KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Teva Pharmaceutical Industries (TEVA) Pension (2016 - 2017)

Teva Pharmaceutical Industries filings provide 5 years of Pension readings, the most recent being $718.0 million for Q3 2017.

On a quarterly basis, Pension changed N/A to $718.0 million in Q3 2017 year-over-year; TTM through Sep 2017 was $718.0 million, a N/A change, with the full-year FY2016 number at $859.0 million, changed N/A from a year prior.
Pension hit $718.0 million in Q3 2017 for Teva Pharmaceutical Industries, up from $712.0 million in the prior quarter.
In the past five years, Pension ranged from a high of $859.0 million in Q4 2016 to a low of $660.0 million in Q1 2017.